Table 2.
Comparison of baseline features between EGPA patients with PN and without PN.
| Characteristics | With PN n = 51 |
Without PN n = 59 |
P value |
|---|---|---|---|
| Demographics | |||
| Age (year, x ± S) | 47±12.9 | 43±14.0 | 0.096 |
| Gender (male/female, n) | 27/24 | 33/26 | 0.753 |
| Time from allergy to EGPA diagnosis (month), median (IQR) | 24(3,84) | 24(6,62) | 0.942 |
| Disease duration(month), median (IQR) | 7(2,19) | 4(2,15) | 0.308 |
| Time from initial symptoms to EGPA diagnosis (month), median (IQR) | 12(0,48) | 6 (0,42) | 0.423 |
| Clinical manifestation [n (%)] | |||
| Weight loss | 25(49.0) | 16(27.1) | 0.018∗ |
| Fever | 24(47.1) | 21(35.6) | 0.223 |
| Arthritis or joint pain | 12(23.5) | 5(8.5) | 0.029∗ |
| Myalgia | 14(27.5) | 8(13.6) | 0.069 |
| Allergic rhinitis | 15(29.4) | 25(42.4) | 0.159 |
| Asthma | 40(78.4) | 45(76.3) | 0.787 |
| Cutaneous vasculitis | 26(51.0) | 33(55.9) | 0.604 |
| Renal involvement | 16(31.4) | 12(20.3) | 0.185 |
| Digestive tract involvement | 20(39.2) | 16(27.1) | 0.178 |
| CNS involvement | 11(21.6) | 8(13.6) | 0.268 |
| Heart involvement | 20(39.2) | 20(33.9) | 0.563 |
| Ear involvement | 8(15.7) | 6(10.2) | 0.387 |
| Sinusitis | 29(56.9) | 35(59.3) | 0.794 |
| Eos count (×109/L), median (IQR) | 3.3(1.3,9.1) | 2.7(1.3,5.8) | 0.827 |
| Clinical score | |||
| BVAS [recent 4 weeks, median (IQR)] | 18(14,22) | 12(8,16) | <0.0001∗ |
| FFS ≥1[n (%)] | 31(60.8) | 25(42.4) | 0.054 |
PN: peripheral neuropathy; CNS: Central Nervous System; Eos: eosinophil; BVAS: Birmingham Vasculitis Activity Score; FFS: five factor score; ∗P < 0.05.